Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Equity

Inhibikase Therapeutics (IKT) Net Margin (2020 - 2023)

Historic Net Margin for Inhibikase Therapeutics (IKT) over the last 4 years, with Q4 2023 value amounting to 440356600.0%.

  • Inhibikase Therapeutics' Net Margin fell 4403497803600.0% to 440356600.0% in Q4 2023 from the same period last year, while for Sep 2024 it was 2006393700.0%, marking a year-over-year decrease of 20063875218800.0%. This contributed to the annual value of 7711.98% for FY2023, which is 69741900.0% up from last year.
  • Latest data reveals that Inhibikase Therapeutics reported Net Margin of 440356600.0% as of Q4 2023, which was down 4403497803600.0% from 5993.38% recorded in Q3 2023.
  • Over the past 5 years, Inhibikase Therapeutics' Net Margin peaked at 187.4% during Q1 2021, and registered a low of 440356600.0% during Q4 2023.
  • For the 4-year period, Inhibikase Therapeutics' Net Margin averaged around 27549285.01%, with its median value being 5660.72% (2023).
  • Its Net Margin has fluctuated over the past 5 years, first soared by 2000000000bps in 2022, then plummeted by 2000000000bps in 2023.
  • Inhibikase Therapeutics' Net Margin (Quarter) stood at 708.85% in 2020, then tumbled by -36487bps to 259342.54% in 2021, then soared by 97bps to 6819.64% in 2022, then tumbled by -6457080bps to 440356600.0% in 2023.
  • Its Net Margin stands at 440356600.0% for Q4 2023, versus 5993.38% for Q3 2023 and 5328.07% for Q2 2023.